Abstract: Abstract of the Disclosure Disclosed herein are methods and compounds for screening and identifying ligands of G protein-coupled receptors (GPCRs). Also disclosed are chimeric G proteins and methods for detecting the activation or inhibition of GPCRs.
Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged.
Abstract: The present invention provides SERF2, a nucleic acid encoding said SERF2 or a cell expressing SERF2 for use as a medicament, in particular for use for use in treating or preventing an atrophy disease or condition or for increasing cellular growth in a patient such as sarcopenia, cachexia, dystrophy, hypoplasia, hypotonia, or muscle loss, as well as in vitro methods suitable for cell culture proliferation and pharmaceutical compositions.
Type:
Grant
Filed:
December 13, 2013
Date of Patent:
May 2, 2017
Assignee:
SIMU TRADE CONSULTING GMBH & CO. LEASING KG
Abstract: Provided are compositions and methods for use in assembling and expressing a plurality of transcription units using, in one aspect, homologous recombination in yeast. Yeast containing the plurality of transcription units, and isolated transcription units, are also provided. Kits for use in making the yeast and the transcript units are further included.
Type:
Grant
Filed:
June 17, 2015
Date of Patent:
April 25, 2017
Assignees:
New York University, Johns Hopkins University
Abstract: The invention relates to tetracycline products produced by genetically engineered cells, and to therapeutic methods using such tetracyclines. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.
Type:
Grant
Filed:
January 28, 2013
Date of Patent:
April 25, 2017
Assignee:
Univerza v Ljubljani
Inventors:
Hrvoje Petkovic, Peter Raspor, Urska Lesnik
Abstract: The present disclosure is directed to adeno-associated viral vector monoclonal antibody constructs and compositions thereof, methods of improving locomotor function after spinal cord injury, methods of treating neurodegenerative diseases.
Type:
Grant
Filed:
August 4, 2015
Date of Patent:
April 18, 2017
Assignee:
The Research Foundation for The State University of New York
Abstract: Compositions and methods of treatments of cells are provided for altering the phenotype of a cell by administering an oligonucleotide complex to the cell, the complex having two strands and chemical modifications.
Type:
Grant
Filed:
August 13, 2014
Date of Patent:
April 11, 2017
Assignee:
THE GENERAL HOSPITAL CORPORATION
Inventors:
David R. Tabatadze, Paul C. Zamecnik, Malay K. Raychowdhury, Horacio F. Cantiello
Abstract: The present invention relates to the use of increased culture pH, relative to standard insect cell culture conditions, during baculovirus infection of lepidopteran insect cells to enable production of recombinant chikungunya (CHIKV) virus like particles (VLPs). The invention further relates to adapted insect cell lines derived from insect cells such as Sf21, which can grow robustly at elevated culture pH, the use of said cell lines to recombinantly produce pH sensitive proteins in the correct conformation and increase expression of recombinant proteins relative to standard insect cell lines. In some embodiments of the invention, the cells are useful for recombinant production of CHIKV VLPs. The invention also relates to a method for the production of a pH-adapted lepidopteran insect cell line. In some embodiments of said method, the cell line is produced and/or maintained in reduced phosphate serum-free insect cell media.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
April 4, 2017
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
James M. Wagner, Shyamsundar Subramanian, David Pajerowski
Abstract: The present invention relates to a technology to provide segmental aneuploidy progeny strains of Trichoderma reesei. In particular, the present invention relates to a method to produce segmental aneuploidy progeny strains of Trichoderma reesei via sexual crossing of two parent haploid strains with chromosome heterozygosity (e.g. one having scaffold M and scaffold 33, the other having scaffold F and scaffold X), preferably at least one of which includes a non-homologous end joining (NHEJ) gene. The present invention also relates to stable, segmental aneuploidy progeny strains of richoderma reesei thus produced which particularly exhibit enhanced gene expression or activities of carbohydrate-active enzymes (CAZymes) and more particularly prevent returning to euploidy for an extended period of time.
Abstract: Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.
Abstract: The present invention relates to an engineered biological system, and in particular an Escherichia coli host. The host is incorporated with a DNA construct for production of at least a first polypeptide. The first polypeptide may be an authentic basic fibroblast growth factor (bFGF). The DNA construct has an insert including, for example, in the sequence of, an expression cassette, an intein sequence and DNA coding for the first polypeptide. The DNA construct is configured to effect the host to secrete the basic fibroblast growth factor (bFGF) in the cytoplasm of the host and/or to excrete to cell medium in which the host is cultured.
Abstract: Provided herein are methods and compositions for analyzing nucleic acids associated with single cells using nucleic acid barcodes. According to some embodiments, a method for producing one or more polynucleotides of interest comprises: obtaining a plurality of RNAs associated with one or more samples, wherein the samples are obtained from one or more subjects, each RNA is associated with a single sample, and the RNAs associated with each sample are present in a separate reaction volume; adding an adapter molecule to the RNAs associated with each sample, wherein the adapter molecule is generated using an enzymatic reaction and comprises a universal priming sequence, a barcode sequence, and a binding site; and incorporating the barcode sequence into one or more polynucleotides associated with each sample, thereby producing the one or more polynucleotides of interest.
Abstract: The invention relates to a method for the simultaneous integration of two or more copies of a polynucleotide of interest into the chromosome of a fungal host cell comprising at least two pairs of recognition sequences of a site-specific recombinase, each pair flanking a resident negative selection marker; transformation of the cell with a construct carrying a gene of interest also flanked by the recognition sequences to ensure double-crossover events after transient expression of the recombinase, followed by selection for excision of all negative selection markers from the cell.
Abstract: Provided are an Aspergillus mutant strain which can dramatically enhance production of a heterologous enzyme when a saccharifying enzyme gene is transferred into the strain to perform transformation and a transformant having a saccharifying enzyme gene transferred into the Aspergillus mutant strain. The Aspergillus mutant strain has been completely or partially deficient in three genes of Aspergillus oryzae strain HO2 (accession number: NITE BP-01750): a prtR gene coding for a transcription factor; a pepA gene coding for an extracellular acid protease; and a cpI gene coding for an extracellular acid carboxypeptidase.
Abstract: Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells.
Abstract: Provided is a standard plasmid for assaying a genetically modified plant, a method for quantitatively analyzing a target transgene within the genetically modified plant using the standard plasmid, and a kit for quantitatively analyzing the genetically modified plant including the standard plasmid, wherein the standard plasmid of the present invention is possible to be utilized for assaying a genome containing a 5-enoyl-4-pyruvylshikimate-3-phosphate synthase (EPSPS) gene or a cry1Ab gene, and in particular, significantly useful as a standard material capable of analyzing whether the genetically modified plant such as soybean RRS or GM maize MON810 is incorporated or an incorporation ratio thereof.
Type:
Grant
Filed:
November 16, 2015
Date of Patent:
February 7, 2017
Assignee:
KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCE
Inventors:
Hyong Ha Kim, Woo Jeong Kim, Su Kyung Lee, Jung Keun Suh, Young Hye Seo
Abstract: The present invention relates to the use (i) of a level of expression of a long RBM39 protein isoform, termed RBM39L, and (ii) of a level of expression of a short RBM39 protein isoform, termed RBM39C, as a marker for the efficacy of an active agent capable of preventing and/or treating HIV infection.
Type:
Grant
Filed:
March 4, 2013
Date of Patent:
January 31, 2017
Assignees:
ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITE DE MONTPELLIER, INSTITUT CURIE
Abstract: The present invention recognizes that diagnosis and prognosis of many conditions can depend on the enrichment of rare cells, especially tumor cells, from a complex fluid sample such as a blood sample. In particular, the present invention is directed to methods and compositions for detecting a non-hematopoietic cell, e.g., a non-hematopoietic tumor cell, in a blood sample via, inter alia, removing red blood cells (RBCs) from a blood sample using a non-centrifugation procedure, removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and assessing the presence, absence and/or amount of said enriched non-hematopoietic cell.
Type:
Grant
Filed:
March 2, 2015
Date of Patent:
January 31, 2017
Assignee:
AVIVA BIOSCIENCES CORPORATION
Inventors:
Ping Lin, Douglas T. Yamanishi, George Walker, Junquan Xu, Mingxian Huang, Guoliang Tao, Lei Wu, Xiaobo Wang, Joe Ouyang, Jing Cheng, Jia Xu
Abstract: The present invention provides trans-complementation systems for expressing gene products in plants. In general, the invention provides systems including a carrier vector and a producer vector, both based on plant viruses. The producer vector is defective for at least one function needed for successful systemic infection of a plant, e.g., replication, cell-to-cell movement, or long distance movement. The carrier vector supplies the missing function in trans. Certain producer vectors lack a functional coat protein coding sequence, in which case the corresponding producer vector supplies coat protein in trans. The invention also provides novel plant viral vectors and methods of use, e.g., to produce polypeptides or active RNAs in plants.